Positively Aware Tivicay

Tivicay

dolutegravir (DTG)

Recommended as component of initial regimen for most people
Integrase Inhibitor

Standard Dose

One 50 mg tablet once daily without regard to food, for people on HIV therapy for the first time (treatment-naïve) or treatment-experienced people who have never taken an INSTI. One 50 mg tablet twice daily, without regard to food, for people who have or who are suspected to have certain INSTI drug resistance or who are taking certain other medications. Must be taken in combination with another antiretroviral(s) which does not contain this medication or medication from the same drug class.

Tivicay is approved for adults and children weighing at least 66 pounds (30 kg). For patients weighing 66 pounds (30 kg) to 88 pounds (40 kg), the dose is one 10 mg tablet and one 25 mg tablet (35 mg total dose) once daily without regard to food. For patients weighing at least 88 pounds (40 mg), the dose is one 50 mg tablet once daily without regard to food.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Not recommended for people with severe liver impairment. Use with caution in people with severe kidney impairment who have INSTI drug resistance or suspected resistance, because Tivicay levels may be decreased.

Manufacturer

ViiV Healthcare
viivhealthcare.com
tivicay.com
(877) 844-8872

AWP

50 mg tablets: $2,088.59/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments